Skip to content
Screener

MeiraGTx Holdings plc MGTX Cash & Equivalents

Cash & Equivalents at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$2.47B+22.3%
Opus Genetics logo
Opus GeneticsIRD
$59.96M+43.5%
Regenxbio logo
RegenxbioRGNX
$36.49M-54.1%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$121.19M+6.4%
Prime Medicine logo
Prime MedicinePRME
$61.14M-9.4%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$72.49M-45.7%

Other financials

Income statement

See full
Revenue$293.0K-84.8%
Operating income-$40.8M+1.9%
Net income-$46.3M-15.8%
EPS (diluted)-$0.57-11.8%

Balance sheet

See full
Total debt$62.7M-22.5%
Total equity-$58.1M-276%
Total assets$244.7M+9.2%

Cash flow

See full
Operating cash flow$17.8M+148%
CapEx$2.0M+17.4%
Free cash flow$15.8M+141%

Valuation

See full
Market cap$1.18B+85.4%
Enterprise value$1.18B+71.1%
P/S14.9×-2.0×

Profitability

See full
Operating margin-597.9%-207pp
Net margin-615.3%
FCF margin-441.5%-126pp

Returns & leverage

See full
Return on equity-379.5%
Debt / equity27.2×+26.1×
Current ratio0.5×-1.0×

Where this comes from

Reported directly by MeiraGTx Holdings plc in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: MeiraGTx Holdings plc’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-060739
Line itemMarch 31, 2026December 31, 2025
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$71,541$65,931
Accounts receivable - related party3,2633,000
Prepaid expenses6,0316,017
Tax incentive receivable14,69615,286
Other current assets6701,527
Total Current Assets96,20191,761

Item 1. Financial Statements (Unaudited)

FAQ

What is MeiraGTx Holdings plc's cash & equivalents?
MeiraGTx Holdings plc (MGTX) reported cash & equivalents of $71.54M in Q1 2026.
How has MeiraGTx Holdings plc's cash & equivalents changed year-over-year?
MeiraGTx Holdings plc's cash & equivalents increased by 7.5% year-over-year, from $66.52M to $71.54M.
What is the long-term trend for MeiraGTx Holdings plc's cash & equivalents?
Over 5 years (2020 to 2025), MeiraGTx Holdings plc's cash & equivalents has grown at a -20.6% compound annual growth rate (CAGR), from $209.52M to $65.93M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about MeiraGTx Holdings plc's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude